A detailed history of Carmignac Gestion transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Carmignac Gestion holds 1,933,531 shares of CLSD stock, worth $1.97 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
1,933,531
Previous 2,132,744 9.34%
Holding current value
$1.97 Million
Previous $2.77 Million 11.44%
% of portfolio
0.04%
Previous 0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.93 - $1.35 $185,268 - $268,937
-199,213 Reduced 9.34%
1,933,531 $2.46 Million
Q3 2023

Nov 13, 2023

SELL
$0.82 - $1.27 $219,432 - $339,852
-267,600 Reduced 11.15%
2,132,744 $1.86 Million
Q3 2022

Nov 10, 2022

BUY
$1.08 - $1.83 $10,800 - $18,300
10,000 Added 0.42%
2,400,344 $2.71 Million
Q2 2022

Aug 12, 2022

SELL
$1.3 - $2.49 $123,900 - $237,316
-95,308 Reduced 3.83%
2,390,344 $3.51 Million
Q4 2021

Feb 11, 2022

BUY
$2.72 - $5.72 $27,200 - $57,200
10,000 Added 0.4%
2,485,652 $6.84 Million
Q3 2021

Nov 12, 2021

SELL
$4.83 - $7.2 $4.56 Million - $6.8 Million
-944,225 Reduced 27.61%
2,475,652 $14.9 Million
Q2 2021

Aug 13, 2021

SELL
$2.32 - $5.38 $280,914 - $651,431
-121,084 Reduced 3.42%
3,419,877 $16.7 Million
Q4 2020

Feb 12, 2021

BUY
$1.32 - $2.74 $1.45 Million - $3.01 Million
1,100,000 Added 45.06%
3,540,961 $9.7 Million
Q3 2020

Nov 13, 2020

BUY
$1.45 - $2.0 $729,861 - $1.01 Million
503,353 Added 25.98%
2,440,961 $3.76 Million
Q2 2020

Aug 13, 2020

SELL
$1.55 - $2.41 $66,495 - $103,389
-42,900 Reduced 2.17%
1,937,608 $3.64 Million
Q1 2020

May 14, 2020

BUY
$1.32 - $3.77 $2.61 Million - $7.47 Million
1,980,508 New
1,980,508 $3.37 Million

Others Institutions Holding CLSD

About Clearside Biomedical, Inc.


  • Ticker CLSD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,190,700
  • Market Cap $61.4M
  • Description
  • Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...
More about CLSD
Track This Portfolio

Track Carmignac Gestion Portfolio

Follow Carmignac Gestion and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

News

Stay updated on Carmignac Gestion with notifications on news.